Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (abbreviated as “GIBH”) is the result of joint effects of Chinese Academy of Sciences, the People’s Government of Guangdong Province and the People’s Government of Guangzhou Municipality. It is officially approved by the Central Institutional Organization Commission in March 2006 and is the first research institute that is under the joint management of CAS and local government. Currently, GIBH is engaged in research areas including stem cell and regenerative medicine, chemical biology, immunology and infectious diseases, public health, and the development of novel scientific equipment.
Aimed to achieve the goal of "Healthy China" strategy and satisfy human health demands, GIBH is exploring disease mechanism with the cutting-edge technologies and developing innovative protocols for disease control and prevention. It provides excellent R&D platform in biomedicine and functions as an incubator for bioengineering and pharmaceutical industries to support local economic development as well as national strategic science and technology programs.
GIBH currently consists of four core research units（South China Institute of Stem Cell and Regenerative Medicine, Institute of Chemical Biology, Center for Infection and Immunity and Institute for Public Health）and a Drug Discovery Pipeline Core Transformation Unit. It provides state-of-the-art core facility and animal center, as well as Centers for Information Supercomputing. GIBH has established several key laboratories including CAS Regenerative Medicine Key Laboratory, Guangdong Province Stem Cell and Regenerative Medicine Key Laboratory and Guangdong Province Biomedical Computing Key Laboratory. Together with Guangzhou Respiratory Disease Institute, a joint Respiratory Disease National Key Laboratory has been established. These research units are the cornerstones for the coming Guangzhou Regenerative Medicine and Health Guangdong Laboratory.
GIBH recruits employees and graduate students worldwide. Currently, it has 381 employees and 304 graduate students and 82.7% of them are aged under 35. In addition, GIBH has recruited 35 senior scientists and most of them are trained overseas.
Researches in GIBH are funded by National Natural Science Foundation, CAS, Guangdong Province and Guangzhou municipal government, including six national major research plan projects, four national key R&D plan project, one CAS Strategic Priority Research Program (class A), one national major scientific research device and equipment development project, and one National Natural Science Foundation Innovative Study. Researches in GIBH have resulted in more than 1200 peer-reviewed scientific papers and won many prestigious awards including National Natural Science Award Second Prize, the Achievements of Outstanding Science and Technology China Academy Award, Southern Guangdong Special Contribution Award and Southern Guangdong Innovation Award, Guangdong Province Science and Technology Award First Prize (three times) and Guangzhou Science and Technology Award First Prize (three times).
GIBH provides Ph.D. programs in Biology, Basic Medicine and Medicinal Chemistry and master programs in Chemical Engineering and Bioengineering. In addition, GIBH has collaborative educational programs with China University of Science and Technology, Jilin University, Anhui Universities, South China University of Technology, Guangzhou Medical University etc.. Moreover, GIBH provides academic training for international students at master or Ph.D. level and has accepted applicants from Spain, Germany, Russia, India etc..
GIBH is committed to promote local industry development with innovative technology and competitive intellectual property. As of December 2017，it has filed 550 patent applications, among which 430 are domestic patents, 74 are international patents and 46 are PCTs. A total of 237 patents are authorized (212 authorized domestic patents and 15 authorized international patents). The patent "A Construction Method of Immunodeficient Mice Model" won the 19th National Outstanding Innovation Award and the 4th Guangdong Outstanding Innovation Award. The anti-Alzheimer's Disease Class 1.1 candidate drug GIBH130, the anti-leukemia Class 1.1 drug GZD824 and the anti-neoplastic Class 1 new drug ASK120067 have been approved by CFDA for clinical trials. GIBH received the title of "Guangdong New R&D Institute" in 2015.
GIBH highly values international cooperation and has established cooperation with Max Planck Society, University of Auckland, University of Hong Kong and Chinese University of Hong Kong. The Max Plank-GIBH Research Center is the first international research center of Max Plank Society in China and the GIBH-Hong Kong Center is the first registered entity of science and technology in Hong Kong on behalf of CAS. GIBH has successfully hosted "Guangzhou International Stem Cell and Regenerative Medicine Forum” for ten consecutive years, which invited many world famous stem cell researchers including Nobel Laureates and promotes regenerative medicine research in South China.
GIBH will follow the guidance of Socialism with Chinese Characteristics in the New Era proposed by General Secretary Xi Jinping to earnestly implement the "First Mover" plan of the CAS and deeply implement the "One-Three-Five" planning; it will take the construction of the International Scientific Innovation Center in the Guangdong-Hong Kong-Macau Greater Bay Area and Guangdong Provincial Laboratory as the opportunity to give full play to the strength of national strategic technologies and continue to make contributions to the national strategy of "Healthy China".